Our early studies demonstrated the inhibitory role of PD-1/PD-L1 signaling in anti-tumor immune response (Freeman et al., 2000; Iwai et al., 2002; Iwai et al., 2005; Okazaki et al., 2013). The gene discussed is PDCD1; the disease is neoplasm.